Novo Nordisk’s Ozempic and Wegovy May Leave You Blind
3 minute of reading
A preliminary study by researchers at Massachusetts Eye and Ear Infirmary, a Harvard affiliate, suggests a possible correlation between taking diabetes medications and weight loss. Nordisk (NYSE: NVO), Ozempic and Wegovy, and a loss of vision that has caused the company’s stock price to fall.
Get notified about the latest news, articles and more!
What’s happened
A report released Tuesday said Novo Nordisk’s weight loss and diabetes drugs Ozempic and Wegovy may be associated with an increased risk of a rare form of vision loss called anterior ischemic optic neuropathy (NAION). Following the release of this report, actions Nordisk According to Benzinga Pro, the stock has been on a downward trend since the start of the week, with losses amounting to about 4%.
These two drugs account for more than 50% of Novo Nordisk’s sales. Any serious problems with these drugs could threaten the company’s profits and share price. However, the market reaction has been relatively mild, indicating that investors are not overly concerned about this initial study.
You may also want to read: Novo Nordisk: Ozempic manufacturer impacts employment in Denmark
It’s important to note that this study is relatively small and has limited statistical power. The results do not prove that the drugs caused the eye complications often associated with diabetes. A much larger study is needed to properly establish any connection.
Because it’s important
Novo Nordisk’s drugs, Ozempic and Vegovi, have become a major pillar of the company’s sales. However, a recent study published in Benzinga Spain found that Mujaro from Eli Lilly (NYSE:LLY) beat Ozempic in weight loss. A new study suggesting a possible link between Novo Nordisk drugs and vision loss could pose an additional challenge for the company.
Retail investors who own Novo Nordisk shares are advised to monitor this situation closely. Any significant threat to these blockbuster drugs would be a major setback to Novo Nordisk’s growth trajectory.
Image by Markus Winkler on Pixabay
This story was created Benzinga Neuro edited by Edgley Romero
You may also want to read: Ozempic vs. Mujaro: Which Weight Loss Drug Is Best?
Get exclusive news 30 minutes before other traders
14-day free trial Benzinga Pro gives you access to exclusive news so you can trade before millions of other investors. Start your 14-day free trial by completing CLICK HERE.
To receive more news on this topic, turn on notifications. Benzinga Spain or follow us on our social networks: X And Facebook.